In its latest attempt to build market credibility, China on Monday launched the Science and Technology Innovation Board, or "STAR Market," on which 25 companies were listed.China Economyread more
Stocks in Asia traded lower on Monday morning, as a Nasdaq-style technology board on the Shanghai Stock Exchange marked its debut.Asia Marketsread more
These box office numbers do not include the cost of production or marketing costs. They also don't count the billions in merchandising that Disney has made over the last...Entertainmentread more
When Cathy Hsu and Tony Hsieh wanted to build an English language app for Chinese children, they decided to follow Facebook and Google's lead.Start-upsread more
Tariffs are the only instrument left for addressing China's systematic and excessive surpluses on its U.S. trades, writes Michael Ivanovitch.US Economyread more
Instagram began tests that hide "like" counts on posts. That means influencers who market products on Instagram will have to rely on different metrics to show success.Technologyread more
Peter Neupert worked for Microsoft and Amazon-backed Drugstore.com, where he got to know Jeff Bezos. He now advises start-ups.Technologyread more
The firing of the tear gas was the latest confrontation between police and protesters who have taken to the streets for over a month to fight a proposed extradition bill and...China Politicsread more
Last week shows that oil prices are not the indicator for Middle East tensions they once were, and worries about global demand and growing U.S. production has changed that...Market Insiderread more
Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
Amazon's new policy for account suspensions doesn't go far enough to protect sellers from potentially unfair and wrongful suspensions, merchants say.Technologyread more
Shares of Mallinckrodt jumped 14 percent Tuesday after the pharmaceutical company posted better-than-expected quarterly results and upped its full-year earnings forecast.
The British drug maker was the biggest gainer on the in afternoon trading, its best daily performance ever.
Earlier Tuesday, Mallinckrodt reported earnings of $2.20 per share, beating consensus estimates by 19 cents. Revenue rose more than 10 percent to $970.6 million, well above analysts' expectations of $921.8 million, according to Thomson Reuters.
The company upped full-year earnings guidance to $8.50 to $8.80 per share, and expects results to come in above the high end of the previously provided range of $8.15 to $8.50, it said in a statement.
"Mallinckrodt's strong performance in the third quarter of fiscal 2016 reflects an ongoing focus on execution in specialty brands- particularly in our commercial and scientific organizations," Mark Trudeau, president and CEO of Mallinckrodt said in the earnings statement.
"We continue to generate compelling new data and clinical evidence for key brands, and are working to bring this data to new physicians and patients."
Shares of the specialty pharmaceutical company ended the day just shy of $77 at $76.91. The stock is positive for the year, up 3 percent but has fallen nearly 38 percent year over year.